Sign Up Today and Learn More About Claris Biotherapeutics Stock
Invest in or calculate the value of your shares in Claris Biotherapeutics or other pre-IPO companies through EquityZen, part of Morgan Stanley.
Claris Biotherapeutics Stock
Claris Biotherapeutics develops biologic therapies for corneal diseases and other disorders affecting the ocular surface.
About Claris Biotherapeutics Stock
Founded
2018
Headquarters
Jersey City, NJ, US
Industries
Software, Artificial Intelligence, Data and Analytics
Claris Biotherapeutics Press Mentions
Stay in the know about the latest news on Claris Biotherapeutics
12家创新药公司完成新一轮融资！
phirda • Jul 31, 2026
Claris Bio获1.18亿美元B轮融资推进角膜治疗研发
donews • Jul 29, 2026
Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments
vcaonline • Jul 29, 2026
Claris Bio unveils development strategy
thepharmaletter • Jul 29, 2026
Claris Bio Unveils Development Strategy, Planned Pivotal Study Supported by $118 Million Series B Financing from Top-Tier Investors, and Multiple Leadership Appointments
biospace • Jul 28, 2026
Claris Biotherapeutics Management
Leadership team at Claris Biotherapeutics
Board Member
Michael Dybbs
Board Member
Matthew Hobson
Join now and verify your accreditation status to gain access to:
- Claris Biotherapeutics Current Valuation
- Claris Biotherapeutics Stock Price
- Claris Biotherapeutics Management
- Available deals in Claris Biotherapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Claris Biotherapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Claris Biotherapeutics Revenue and Financials
- Claris Biotherapeutics Highlights
- Claris Biotherapeutics Business Model
- Claris Biotherapeutics Risk Factors
- Claris Biotherapeutics Research Report from SACRA Research
Trading Claris Biotherapeutics Stock
How to invest in Claris Biotherapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Claris Biotherapeutics through EquityZen funds. These investments are made available by existing Claris Biotherapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Claris Biotherapeutics stock?
Shareholders can sell their Claris Biotherapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 470K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 55K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."